Literature DB >> 19347020

MRI--the perfect surrogate marker for multiple sclerosis?

Frederik Barkhof1, Massimo Filippi.   

Abstract

MRI provides a very sensitive reflection of the histopathological changes in multiple sclerosis. Many short-term studies fail to appreciate the relationship between MRI and clinical findings, although such shortcomings might be argued to reflect a weakness of clinical measures, rather than of MRI.

Entities:  

Mesh：

Year:  2009        PMID： 19347020     DOI： 10.1038/nrneurol.2009.31

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


  13 in total

1.  Concurrent validity of the MS Functional Composite using MRI as a biological disease marker.

Authors:  N F Kalkers; L Bergers; V de Groot; R H Lazeron; M A van Walderveen; B M Uitdehaag; C H Polman; F Barkhof
Journal:  Neurology       Date:  2001-01-23       Impact factor: 9.910

Review 2.  Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment?

Authors:  Douglas S Goodin
Journal:  Ann Neurol       Date:  2006-04       Impact factor: 10.422

3.  Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach.

Authors:  Maria Pia Sormani; Laura Bonzano; Luca Roccatagliata; Gary R Cutter; Gian Luigi Mancardi; Paolo Bruzzi
Journal:  Ann Neurol       Date:  2009-03       Impact factor: 10.422

4.  Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis.

Authors:  J W Thorpe; D Kidd; I F Moseley; B E Kenndall; A J Thompson; D G MacManus; W I McDonald; D H Miller
Journal:  Neurology       Date:  1996-02       Impact factor: 9.910

5.  Eight-year follow-up study of brain atrophy in patients with MS.

Authors:  E Fisher; R A Rudick; J H Simon; G Cutter; M Baier; J-C Lee; D Miller; B Weinstock-Guttman; M K Mass; D S Dougherty; N A Simonian
Journal:  Neurology       Date:  2002-11-12       Impact factor: 9.910

6.  MRI as an outcome in multiple sclerosis clinical trials.

Authors:  M Daumer; A Neuhaus; S Morrissey; R Hintzen; G C Ebers
Journal:  Neurology       Date:  2008-12-10       Impact factor: 9.910

Review 7.  MRI in multiple sclerosis: current status and future prospects.

Authors:  Rohit Bakshi; Alan J Thompson; Maria A Rocca; Daniel Pelletier; Vincent Dousset; Frederik Barkhof; Matilde Inglese; Charles R G Guttmann; Mark A Horsfield; Massimo Filippi
Journal:  Lancet Neurol       Date:  2008-07       Impact factor: 44.182

8.  The pathophysiology of acute optic neuritis. An association of gadolinium leakage with clinical and electrophysiological deficits.

Authors:  B D Youl; G Turano; D H Miller; A D Towell; D G MacManus; S G Moore; S J Jones; G Barrett; B E Kendall; I F Moseley
Journal:  Brain       Date:  1991-12       Impact factor: 13.501

9.  Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis.

Authors:  L K Fisniku; P A Brex; D R Altmann; K A Miszkiel; C E Benton; R Lanyon; A J Thompson; D H Miller
Journal:  Brain       Date:  2008-01-29       Impact factor: 13.501

10.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422
View more
  10 in total

Review 1.  MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials.

Authors:  Frederik Barkhof; Jack H Simon; Franz Fazekas; Marco Rovaris; Ludwig Kappos; Nicola de Stefano; Chris H Polman; John Petkau; Ernst W Radue; Maria P Sormani; David K Li; Paul O'Connor; Xavier Montalban; David H Miller; Massimo Filippi
Journal:  Nat Rev Neurol       Date:  2011-12-06       Impact factor: 42.937

2.  Rostrocaudal analysis of corpus callosum demyelination and axon damage across disease stages refines diffusion tensor imaging correlations with pathological features.

Authors:  Mingqiang Xie; Jennifer E Tobin; Matthew D Budde; Chin-I Chen; Kathryn Trinkaus; Anne H Cross; Dennis P McDaniel; Sheng-Kwei Song; Regina C Armstrong
Journal:  J Neuropathol Exp Neurol       Date:  2010-07       Impact factor: 3.685

3.  A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis.

Authors:  Elliot M Frohman; Gary Cutter; Gina Remington; Hongjiang Gao; Howard Rossman; Bianca Weinstock-Guttman; Jacqueline E Durfee; Amy Conger; Ellen Carl; Katherine Treadaway; Eric Lindzen; Amber Salter; Teresa C Frohman; Anjali Shah; Angela Bates; Jennifer L Cox; Michael G Dwyer; Olaf Stüve; Benjamin M Greenberg; Michael K Racke; Robert Zivadinov
Journal:  Ther Adv Neurol Disord       Date:  2010-01       Impact factor: 6.570

4.  Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010.

Authors:  Stuart D Cook; Suhayl Dhib-Jalbut; Peter Dowling; Luca Durelli; Corey Ford; Gavin Giovannoni; June Halper; Colleen Harris; Joseph Herbert; David Li; John A Lincoln; Robert Lisak; Fred D Lublin; Claudia F Lucchinetti; Wayne Moore; Robert T Naismith; Carlos Oehninger; Jack Simon; Maria Pia Sormani
Journal:  Int J MS Care       Date:  2012

Review 5.  Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis.

Authors:  Natalie J Carter; Gillian M Keating
Journal:  Drugs       Date:  2010-08-20       Impact factor: 9.546

6.  Quantitative assessment of finger motor impairment in multiple sclerosis.

Authors:  Laura Bonzano; Maria Pia Sormani; Andrea Tacchino; Lucia Abate; Caterina Lapucci; Giovanni Luigi Mancardi; Antonio Uccelli; Marco Bove
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

7.  Characterization of relapsing-remitting multiple sclerosis patients using support vector machine classifications of functional and diffusion MRI data.

Authors:  Mariana Zurita; Cristian Montalba; Tomás Labbé; Juan Pablo Cruz; Josué Dalboni da Rocha; Cristián Tejos; Ethel Ciampi; Claudia Cárcamo; Ranganatha Sitaram; Sergio Uribe
Journal:  Neuroimage Clin       Date:  2018-09-04       Impact factor: 4.881

Review 8.  Precision Medicine in Multiple Sclerosis: Future of PET Imaging of Inflammation and Reactive Astrocytes.

Authors:  Pekka Poutiainen; Merja Jaronen; Francisco J Quintana; Anna-Liisa Brownell
Journal:  Front Mol Neurosci       Date:  2016-09-15       Impact factor: 5.639

9.  Cognitive clinico-radiological paradox in early stages of multiple sclerosis.

Authors:  Tomas Uher; Jan Krasensky; Lukas Sobisek; Jana Blahova Dusankova; Zdenek Seidl; Eva Kubala Havrdova; Maria Pia Sormani; Dana Horakova; Tomas Kalincik; Manuela Vaneckova
Journal:  Ann Clin Transl Neurol       Date:  2017-12-15       Impact factor: 4.511

10.  Cytotoxic CD4+ T Cells Drive Multiple Sclerosis Progression.

Authors:  Liesbet M Peeters; Marjan Vanheusden; Veerle Somers; Bart Van Wijmeersch; Piet Stinissen; Bieke Broux; Niels Hellings
Journal:  Front Immunol       Date:  2017-09-20       Impact factor: 7.561
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.